TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35236653

Group type: EXPERIMENTAL
Intervention: Gongning granules plus low-dose hormone therapy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Estrogen progesterone (control group)
Number of subjects: 164
Study: 32889451

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control Episodic Thinking (CET)
Number of subjects: 250
Study: 32187352

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 180

Group type: COMPARATOR
Intervention: Watchful waiting strategy
Number of subjects: 180
Study: 33992289

Group type: EXPERIMENTAL
Intervention: Dance intervention (performed semiweekly for 8 months)
Number of subjects: 112
Study: 33248629

Group type: EXPERIMENTAL
Intervention: Basal diet containing 300 mg/kg of medium-chain α-monoglycerides (MG)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Basal diet (Control group)
Number of subjects: 252
Study: 34342547

Group type: EXPERIMENTAL
Intervention: Expander prosthesis (EP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: DIEP flap
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Reconstructed breasts (both EP and DIEP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BREAST-Q questionnaire
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Objective results
Number of subjects: 68
Study: 33508442

Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 32
Study: 32391740

Group type: EXPERIMENTAL
Intervention: Early and systematic integration of specialist palliative care (consultation with a PC physician every six to eight weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard oncology care
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Early and systematic integration of specialist palliative care
Number of subjects: 126
Study: 35288500

Group type: EXPERIMENTAL
Intervention: Blue-violet light-emitting diode (LED) irradiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 31
Study: 33884643

Group type: EXPERIMENTAL
Intervention: Nurse-led, community-based diabetes self management education and support program (6 sessions, supported by educational materials)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 32316589

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) training for 12 weeks, 3 times a week at 70% intensity
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 36329915

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT) delivered via videoconference, 14 sessions over 16 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group (no immediate treatment).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Internet-based CBT (treatment group).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group (after treatment).
Number of subjects: 60
Study: 33175090

Group type: EXPERIMENTAL
Intervention: Genetic liability for increased prescription opioid use
Number of subjects: 737473

Group type: EXPERIMENTAL
Intervention: Genetic liability for increased prescription opioid use (multivariable MR)
Number of subjects: 737473

Group type: EXPERIMENTAL
Intervention: Genetic liability for MDD
Number of subjects: 737473
Study: 32690503

Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention (six, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour approach discussion group)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual rehabilitation (six, 30 min weekly group-based exercise sessions)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual rehabilitation
Number of subjects: 260
Study: 35955635

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy heat therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Single-leg interval exercise training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 35
Study: 34948915

Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgical masks
Number of subjects: 68
Study: 35708106

Group type: EXPERIMENTAL
Intervention: LT4 administration 3 hours post-iftar
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: LT4 administration 1 hour pre-suhoor
Number of subjects: 31

Group type: COMPARATOR
Intervention: LT4 administration 30 minutes pre-iftar
Number of subjects: 31
Study: 32744924

Group type: EXPERIMENTAL
Intervention: Full program based on module trainings
Number of subjects: 117

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 117
Study: 36249792

Group type: EXPERIMENTAL
Intervention: Atovaquone 1500 mg BID
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Atovaquone plus standard of care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Atovaquone levels
Number of subjects: 61
Study: 33150888

Group type: EXPERIMENTAL
Intervention: ZnV2‐xInxO4 (x = 0.25, 0.50, 1.00)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ZnVInO4
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ZnVCrO4
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ZnVFeO4
Number of subjects: 5
Study: 35105650

Group type: EXPERIMENTAL
Intervention: Cuff pressure of 45 cmH2O
Number of subjects: 800

Group type: COMPARATOR
Intervention: Cuff pressure of 60 cmH2O
Number of subjects: 800
Study: 33462988

Group type: EXPERIMENTAL
Intervention: Trazpiroben 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36273651

Group type: COMPARATOR
Intervention: Adrenaline (0.2 mg, 2 mL, 1:10000)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (100 mg, 2 mL)
Number of subjects: 130
Study: 33578359

Group type: EXPERIMENTAL
Intervention: NetballSmart Dynamic Warm-up (NSDW)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Power warm-up (PWU)
Number of subjects: 77
Study: 34218315

Group type: EXPERIMENTAL
Intervention: Weekly guidance on nutrition, physical activity, water intake, and health-promoting behaviors
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Underhydration during pregnancy
Number of subjects: 27
Study: 33577964

Group type: EXPERIMENTAL
Intervention: Ubiquinol (300 mg) every 12 h for up to 7 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo every 12 h for up to 7 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ubiquinol (300 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 35986739

Group type: EXPERIMENTAL
Intervention: Piperacillin tazobactam combined with high-frequency chest-wall oscillation (HFCWO)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (conventional treatment with oxygen, antibiotics, antispasmodics, antiasthmatic drugs, phlegmolytic drugs, and HFCWO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Piperacillin tazobactam combined with HFCWO
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 32929540

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 6018

Group type: EXPERIMENTAL
Intervention: Clodronate (CL)
Number of subjects: 6018

Group type: EXPERIMENTAL
Intervention: Ibandronate (IB)
Number of subjects: 6018

Group type: EXPERIMENTAL
Intervention: All bisphosphonates
Number of subjects: 6018

Group type: EXPERIMENTAL
Intervention: Dental health factors
Number of subjects: 6018
Study: 33444396

Group type: EXPERIMENTAL
Intervention: FlowOx™ therapy plus nominal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33377925

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg·kg-1·h-1 infusion)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 34027993

Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab plus thiopurines)
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1437
Study: 35450777

Group type: EXPERIMENTAL
Intervention: Orthodontic patients
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dentists
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-oral-related practitioners
Number of subjects: 240

Group type: COMPARATOR
Intervention: Orthodontists
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Overall observers
Number of subjects: 240
Study: 36361426

Group type: EXPERIMENTAL
Intervention: Foot reflexology applied on specific areas of the feet for 10 consecutive days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group received information on foot care and health
Number of subjects: 17
Study: 32011785

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for 2 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: Stress management education (active control)
Number of subjects: 202
Study: 35477371

Group type: EXPERIMENTAL
Intervention: CSM-based intervention program
Number of subjects: 78
Study: 33773802

Group type: EXPERIMENTAL
Intervention: Video training materials
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written material (Control group)
Number of subjects: 60
Study: 35296532

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 32957983

Group type: EXPERIMENTAL
Intervention: ASV-V (ResMed® devices)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ASV-F (Philips® devices)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Auto-EPAP usage
Number of subjects: 177
Study: 34311440

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (85 mg of caffeine in 25-ml mouth rinse for 5 s every 5 min during exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (water mouth rinse)
Number of subjects: 10
Study: 32336266

Group type: EXPERIMENTAL
Intervention: Drug trial with presumed superiority of new drug versus equipoise
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Drug trial funded by public sources
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Diagnostic study
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Drug trial with random treatment allocation
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Diagnostic study factors tested (common vs. rare disease, genetic vs. protein analysis, automatic vs. reporting on request)
Number of subjects: 1140
Study: 34779272

Group type: EXPERIMENTAL
Intervention: Discharge platelet count (PC)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Discharge mean platelet volume (MPV)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: In-hospital platelet count (PC) difference
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: In-hospital PC decrease
Number of subjects: 252
Study: 34526078

Group type: EXPERIMENTAL
Intervention: Complex psychosocial intervention providing advice, information, and care on emotional, psycho-social, and communicative levels during and after the cancer experience
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 560
Study: 35611396

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (cisplatin and 5-fluorouracil chemotherapy plus radiotherapy)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 96
Study: 33248746

Group type: EXPERIMENTAL
Intervention: L4/5 zygapophyseal mobilizations
Number of subjects: 24
Study: 33922493

Group type: EXPERIMENTAL
Intervention: Tart Cherry Concentrate (30 mL twice per day for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (isocaloric, 30 mL twice per day for 3 months)
Number of subjects: 50
Study: 34409935

Group type: EXPERIMENTAL
Intervention: Play2Sleep
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison home visit
Number of subjects: 63
Study: 34600487

Group type: EXPERIMENTAL
Intervention: ERAS treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional treatment (Control)
Number of subjects: 116
Study: 33176512

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle medicine interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacologic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0
Study: 33267610

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type 1 MI
Number of subjects: 0
Study: 32040761

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Anti-TNF agents
Number of subjects: 2
Study: 35861797

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with everolimus‐eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft Surgery (CABG)
Number of subjects: 1905
Study: 34364386

Group type: EXPERIMENTAL
Intervention: Booklet intervention delivered by general practitioner
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Modification of antihypertensive treatment
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Initiation of antihypertensive treatment
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Booklet intervention
Number of subjects: 1095
Study: 33091035

Group type: EXPERIMENTAL
Intervention: Breast cancer awareness intervention (not specified in detail)
Number of subjects: 1758

Group type: EXPERIMENTAL
Intervention: Cervical cancer awareness intervention (not specified in detail)
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Comparison of urban vs rural women in South Africa
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Comparison of married vs unmarried women in Uganda
Number of subjects: 1758
Study: 35803849

Group type: EXPERIMENTAL
Intervention: Day-case LSG (DC LSG)
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Conventional hospitalization LSG (CH LSG)
Number of subjects: 1544
Study: 33357122

Group type: EXPERIMENTAL
Intervention: Cooling bandana
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cooling bandana and cooling vest
Number of subjects: 84

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 84
Study: 35832107

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation at 2 Hz for 5 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (nonstimulated)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation
Number of subjects: 17
Study: 35441200

Group type: EXPERIMENTAL
Intervention: Lomecel-B (25, 50, 100, or 200 million cells)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lomecel-B
Number of subjects: 150
Study: 32844599

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg twice daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 33273421

Group type: EXPERIMENTAL
Intervention: Just-in-time information (JITI) app
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Limited training with JITI app
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Extended training with JITI app
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 32507430

Group type: COMPARATOR
Intervention: Body acupressure (GB21, GB30, BL32, LI4, SP6 points for two minutes at cervical dilation of four, six, and eight centimeters)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ear acupressure (adhesive auriculotherapy-specific Vaccaria seeds on zero, genitalia, Shen Men, thalamic, and uterine 1 and 2 acupoints, compressed every thirty minutes for thirty seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine care services)
Number of subjects: 0
Study: 33966730

Group type: EXPERIMENTAL
Intervention: Silicone gel plus Me‐EGF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Silicone gel only
Number of subjects: 60

Group type: COMPARATOR
Intervention: No scar treatment
Number of subjects: 60
Study: 32827435

Group type: EXPERIMENTAL
Intervention: OW semaglutide 1 mg
Number of subjects: 1405

Group type: COMPARATOR
Intervention: OD empagliflozin 25 mg
Number of subjects: 1405
Study: 35311327

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32307515

Group type: EXPERIMENTAL
Intervention: POD programme (intervention group)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 714
Study: 36126648

Group type: EXPERIMENTAL
Intervention: Hemostatic spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional hemostatic methods
Number of subjects: 40
Study: 33556464

Group type: EXPERIMENTAL
Intervention: Early AIT with intravenous anakinra (100 mg every 8 hours for 3 days, with tapering) alone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Early AIT with intravenous anakinra plus glucocorticoid (intravenous methylprednisolone, 1-2 mg/kg daily, with tapering)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Late rescue treatment (anakinra or tocilizumab)
Number of subjects: 128
Study: 35019020

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (sterile tap water)
Number of subjects: 20
Study: 33051423

Group type: EXPERIMENTAL
Intervention: Group 1 (62±2 mL/(kg·min))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 2 (72±2 mL/(kg·min))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 3 (82±2 mL/(kg·min))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 45
Study: 35007749

Group type: EXPERIMENTAL
Intervention: Operative treatment with a hook plate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nonoperative treatment (physiotherapy)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (nonoperative and operative)
Number of subjects: 124
Study: 33051072

Group type: EXPERIMENTAL
Intervention: Preoperative femoral nerve block (PreopFNB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: CONTROL (usual care)
Number of subjects: 73
Study: 33930548

Group type: EXPERIMENTAL
Intervention: Complement genes in response to Vibrio anguillarum infection
Number of subjects: 112
Study: 35581660

Group type: EXPERIMENTAL
Intervention: Transmucosal diamorphine (buccal and intranasal routes)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 13
Study: 32988292

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 32763320

Group type: EXPERIMENTAL
Intervention: High submuscular (HSM) placement of inflatable penile prosthesis (IPP) reservoirs via the Five-Step Technique (FST)
Number of subjects: 297
Study: 35686330

Group type: EXPERIMENTAL
Intervention: aprocitentan 12.5 mg
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: aprocitentan 25 mg
Number of subjects: 730

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 730
Study: 35081947

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) applied every 4 days, a total of three times during the study period.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Kinesiotaping (placebo group).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) at D30.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Kinesiotaping (placebo group) at D30.
Number of subjects: 50
Study: 33228621

Group type: EXPERIMENTAL
Intervention: Higher perceived susceptibility of oral diseases
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Higher perceived severity of oral diseases
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Flossing weekly
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Higher general anxiety level
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Stronger perceived susceptibility, greater severity of oral diseases, less performing of oral health behaviors, higher DMFT score
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Other HBM variables (perceived susceptibility, self‐efficacy beliefs, cues to action, perceived barriers)
Number of subjects: 1207
Study: 34271982

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 33031757

Group type: EXPERIMENTAL
Intervention: Cobitolimod 2 × 250 mg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cobitolimod 2 × 31 mg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cobitolimod 2 × 125 mg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cobitolimod 4 × 125 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 35996236

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with early enteral nutrition
Number of subjects: 122

Group type: COMPARATOR
Intervention: Early enteral nutrition
Number of subjects: 122
Study: 33978491

Group type: EXPERIMENTAL
Intervention: 50 g/day dried plum
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 g/day dried plum
Number of subjects: 48
Study: 32868360

Group type: EXPERIMENTAL
Intervention: One dose of ivermectin-based mass drug administration (MDA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two doses of ivermectin-based mass drug administration (MDA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ivermectin-based MDA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: One-dose and two-dose MDA
Number of subjects: 20
Study: 34044848

Group type: EXPERIMENTAL
Intervention: Immediate weight-bearing (IWB) in a walking boot and range of motion (ROM) exercise within 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-weight-bearing (NWB) and immobilisation in a cast for 6 weeks
Number of subjects: 0